Skip to main content
NCBI home page
Molecular Medicine logoLink to Molecular Medicine
. 1997 Oct;3(10):636–651.

Recent advances in the treatment of malignant melanoma with gene therapy.

E M Hersh 1, A T Stopeck 1
PMCID: PMC2230237  PMID: 9392001

Full text

PDF
636

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdel-Wahab Z. A., Osanto S., Darrow T. L., Barber J. R., Vervaert C. E., Gangavalli R., McCallister T. J., Seigler H. F. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. Cancer Gene Ther. 1994 Sep;1(3):171–179. [PubMed] [Google Scholar]
  2. Abdel-Wahab Z., Dar M., Osanto S., Fong T., Vervaert C. E., Hester D., Jolly D., Seigler H. F. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. Cancer Gene Ther. 1997 Jan-Feb;4(1):33–41. [PubMed] [Google Scholar]
  3. Aebersold P., Hyatt C., Johnson S., Hines K., Korcak L., Sanders M., Lotze M., Topalian S., Yang J., Rosenberg S. A. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst. 1991 Jul 3;83(13):932–937. doi: 10.1093/jnci/83.13.932. [DOI] [PubMed] [Google Scholar]
  4. Albertini M. R., Emler C. A., Schell K., Tans K. J., King D. M., Sheehy M. J. Dual expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle-mediated gene transfer. Cancer Gene Ther. 1996 May-Jun;3(3):192–201. [PubMed] [Google Scholar]
  5. Albino A. P., Lloyd K. O., Houghton A. N., Oettgen H. F., Old L. J. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med. 1981 Dec 1;154(6):1764–1778. doi: 10.1084/jem.154.6.1764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Apasov S., Redegeld F., Sitkovsky M. Cell-mediated cytotoxicity: contact and secreted factors. Curr Opin Immunol. 1993 Jun;5(3):404–410. doi: 10.1016/0952-7915(93)90060-6. [DOI] [PubMed] [Google Scholar]
  7. Arca M. J., Krauss J. C., Aruga A., Cameron M. J., Shu S., Chang A. E. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther. 1996 Jan-Feb;3(1):39–47. [PubMed] [Google Scholar]
  8. Arienti F., Sulé-Suso J., Belli F., Mascheroni L., Rivoltini L., Melani C., Maio M., Cascinelli N., Colombo M. P., Parmiani G. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther. 1996 Oct 20;7(16):1955–1963. doi: 10.1089/hum.1996.7.16-1955. [DOI] [PubMed] [Google Scholar]
  9. Arienti F., Sulé-Suso J., Melani C., Maccalli C., Belli F., Illeni M. T., Anichini A., Cascinelli N., Colombo M. P., Parmiani G. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum Gene Ther. 1994 Sep;5(9):1139–1150. doi: 10.1089/hum.1994.5.9-1139. [DOI] [PubMed] [Google Scholar]
  10. Bakker A. B., Marland G., de Boer A. J., Huijbens R. J., Danen E. H., Adema G. J., Figdor C. G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 1995 Nov 15;55(22):5330–5334. [PubMed] [Google Scholar]
  11. Bakker A. B., Schreurs M. W., de Boer A. J., Kawakami Y., Rosenberg S. A., Adema G. J., Figdor C. G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994 Mar 1;179(3):1005–1009. doi: 10.1084/jem.179.3.1005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Berd D., Maguire H. C., Jr, McCue P., Mastrangelo M. J. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol. 1990 Nov;8(11):1858–1867. doi: 10.1200/JCO.1990.8.11.1858. [DOI] [PubMed] [Google Scholar]
  13. Berd D., Murphy G., Maguire H. C., Jr, Mastrangelo M. J. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. 1991 May 15;51(10):2731–2734. [PubMed] [Google Scholar]
  14. Brichard V., Van Pel A., Wölfel T., Wölfel C., De Plaen E., Lethé B., Coulie P., Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993 Aug 1;178(2):489–495. doi: 10.1084/jem.178.2.489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cao X., Chen C., Zhang W., Tao Q., Yu Y., Ye T. Enhanced efficacy of combination of IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. Gene Ther. 1996 May;3(5):421–426. [PubMed] [Google Scholar]
  16. Carrel S., Doré J. F., Ruiter D. J., Prade M., Lejeune F. J., Kleeberg U. R., Rümke P., Bröcker E. B. The EORTC Melanoma Group exchange program: evaluation of a multicenter monoclonal antibody study. Int J Cancer. 1991 Jul 30;48(6):836–847. doi: 10.1002/ijc.2910480609. [DOI] [PubMed] [Google Scholar]
  17. Carrel S., Rimoldi D. Melanoma-associated antigens. Eur J Cancer. 1993;29A(13):1903–1907. doi: 10.1016/0959-8049(93)90548-t. [DOI] [PubMed] [Google Scholar]
  18. Chen L., McGowan P., Ashe S., Johnston J., Li Y., Hellström I., Hellström K. E. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994 Feb 1;179(2):523–532. doi: 10.1084/jem.179.2.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cheresh D. A. Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. Cancer Metastasis Rev. 1991 May;10(1):3–10. doi: 10.1007/BF00046839. [DOI] [PubMed] [Google Scholar]
  20. Chong A. S., Scuderi P., Grimes W. J., Hersh E. M. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. J Immunol. 1989 Mar 15;142(6):2133–2139. [PubMed] [Google Scholar]
  21. Cormier J. N., Salgaller M. L., Prevette T., Barracchini K. C., Rivoltini L., Restifo N. P., Rosenberg S. A., Marincola F. M. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am. 1997 Jan-Feb;3(1):37–44. [PMC free article] [PubMed] [Google Scholar]
  22. Cox A. L., Skipper J., Chen Y., Henderson R. A., Darrow T. L., Shabanowitz J., Engelhard V. H., Hunt D. F., Slingluff C. L., Jr Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 1994 Apr 29;264(5159):716–719. doi: 10.1126/science.7513441. [DOI] [PubMed] [Google Scholar]
  23. DeBruyne L. A., Chang A. E., Cameron M. J., Yang Z., Gordon D., Nabel E. G., Nabel G. J., Bishop D. K. Direct transfer of a foreign MHC gene into human melanoma alters T cell receptor V beta usage by tumor-infiltrating lymphocytes. Cancer Immunol Immunother. 1996 Sep;43(1):49–58. doi: 10.1007/s002620050303. [DOI] [PubMed] [Google Scholar]
  24. Dean M., Carrington M., Winkler C., Huttley G. A., Smith M. W., Allikmets R., Goedert J. J., Buchbinder S. P., Vittinghoff E., Gomperts E. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996 Sep 27;273(5283):1856–1862. doi: 10.1126/science.273.5283.1856. [DOI] [PubMed] [Google Scholar]
  25. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539–3543. doi: 10.1073/pnas.90.8.3539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Elder E. M., Lotze M. T., Whiteside T. L. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum Gene Ther. 1996 Mar 1;7(4):479–487. doi: 10.1089/hum.1996.7.4-479. [DOI] [PubMed] [Google Scholar]
  27. Ettinghausen S. E., Rosenberg S. A. Immunotherapy and gene therapy of cancer. Adv Surg. 1995;28:223–254. [PubMed] [Google Scholar]
  28. Fearon E. R., Pardoll D. M., Itaya T., Golumbek P., Levitsky H. I., Simons J. W., Karasuyama H., Vogelstein B., Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990 Feb 9;60(3):397–403. doi: 10.1016/0092-8674(90)90591-2. [DOI] [PubMed] [Google Scholar]
  29. Felgner P. L. Improvements in cationic liposomes for in vivo gene transfer. Hum Gene Ther. 1996 Oct 1;7(15):1791–1793. doi: 10.1089/hum.1996.7.15-1791. [DOI] [PubMed] [Google Scholar]
  30. Fuchs A. C., Granowitz E. V., Shapiro L., Vannier E., Lonnemann G., Angel J. B., Kennedy J. S., Rabson A. R., Radwanski E., Affrime M. B. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J Clin Immunol. 1996 Sep;16(5):291–303. doi: 10.1007/BF01541395. [DOI] [PubMed] [Google Scholar]
  31. Fujiwara T., Grimm E. A., Roth J. A. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol. 1994 Jan;6(1):96–105. doi: 10.1097/00001622-199401000-00014. [DOI] [PubMed] [Google Scholar]
  32. Gabrilovich D. I., Corak J., Ciernik I. F., Kavanaugh D., Carbone D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 1997 Mar;3(3):483–490. [PubMed] [Google Scholar]
  33. Galle P. R., Hofmann W. J., Walczak H., Schaller H., Otto G., Stremmel W., Krammer P. H., Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med. 1995 Nov 1;182(5):1223–1230. doi: 10.1084/jem.182.5.1223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J. J., De Plaen E., Lethé B., Brasseur F., Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994 Mar 1;179(3):921–930. doi: 10.1084/jem.179.3.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Goldfarb R. H., Whiteside T. L., Basse P. H., Lin W. C., Vujanovic N., Herberman R. B. Natural killer cells and gene therapy: potential of gene transfection for optimizing effector cell functions and for targeting gene products into tumor metastases. Nat Immun. 1994 Mar-Jun;13(2-3):131–140. [PubMed] [Google Scholar]
  36. Griffith T. S., Brunner T., Fletcher S. M., Green D. R., Ferguson T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995 Nov 17;270(5239):1189–1192. doi: 10.1126/science.270.5239.1189. [DOI] [PubMed] [Google Scholar]
  37. Guinan E. C., Gribben J. G., Boussiotis V. A., Freeman G. J., Nadler L. M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994 Nov 15;84(10):3261–3282. [PubMed] [Google Scholar]
  38. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996 Nov 22;274(5291):1363–1366. doi: 10.1126/science.274.5291.1363. [DOI] [PubMed] [Google Scholar]
  39. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996 Nov 22;274(5291):1363–1366. doi: 10.1126/science.274.5291.1363. [DOI] [PubMed] [Google Scholar]
  40. Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J Surg. 1992 Mar-Apr;16(2):251–260. doi: 10.1007/BF02071529. [DOI] [PubMed] [Google Scholar]
  41. Hollingsworth S. J., Darling D., Gäken J., Hirst W., Patel P., Kuiper M., Towner P., Humphreys S., Farzaneh F., Mufti G. J. The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma. Br J Cancer. 1996 Jul;74(1):6–15. doi: 10.1038/bjc.1996.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Hom S. S., Topalian S. L., Simonis T., Mancini M., Rosenberg S. A. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother (1991) 1991 Jun;10(3):153–164. [PubMed] [Google Scholar]
  43. Houghton A. N., Brooks H., Cote R. J., Taormina M. C., Oettgen H. F., Old L. J. Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J Exp Med. 1983 Jul 1;158(1):53–65. doi: 10.1084/jem.158.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Howard M., O'Garra A. Biological properties of interleukin 10. Immunol Today. 1992 Jun;13(6):198–200. doi: 10.1016/0167-5699(92)90153-X. [DOI] [PubMed] [Google Scholar]
  45. Ju D. W., Cao X., Acres B. Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virus. J Cancer Res Clin Oncol. 1996;122(12):716–722. doi: 10.1007/BF01209118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Ju D. W., Cao X., Acres B. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a mixture melanoma model. Cancer Gene Ther. 1997 Mar-Apr;4(2):139–144. [PubMed] [Google Scholar]
  47. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Rivoltini L., Topalian S. L., Miki T., Rosenberg S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3515–3519. doi: 10.1073/pnas.91.9.3515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst. 1994 Feb 16;86(4):299–304. doi: 10.1093/jnci/86.4.299. [DOI] [PubMed] [Google Scholar]
  49. Kim T. S., Russell S. J., Collins M. K., Cohen E. P. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer. 1992 May 8;51(2):283–289. doi: 10.1002/ijc.2910510218. [DOI] [PubMed] [Google Scholar]
  50. Kono K., Ressing M. E., Brandt R. M., Melief C. J., Potkul R. K., Andersson B., Petersson M., Kast W. M., Kiessling R. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res. 1996 Nov;2(11):1825–1828. [PubMed] [Google Scholar]
  51. Koç O. N., Allay J. A., Lee K., Davis B. M., Reese J. S., Gerson S. L. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol. 1996 Feb;23(1):46–65. [PubMed] [Google Scholar]
  52. Ledda M. F., Adris S., Bravo A. I., Kairiyama C., Bover L., Chernajovsky Y., Mordoh J., Podhajcer O. L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med. 1997 Feb;3(2):171–176. doi: 10.1038/nm0297-171. [DOI] [PubMed] [Google Scholar]
  53. Licht T., Pastan I., Gottesman M. M., Herrmann F. The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders. Ann Hematol. 1996 Apr;72(4):184–193. doi: 10.1007/s002770050159. [DOI] [PubMed] [Google Scholar]
  54. Livingston P. O., Natoli E. J., Calves M. J., Stockert E., Oettgen H. F., Old L. J. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A. 1987 May;84(9):2911–2915. doi: 10.1073/pnas.84.9.2911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Luca M., Hunt B., Bucana C. D., Johnson J. P., Fidler I. J., Bar-Eli M. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res. 1993 Feb;3(1):35–41. doi: 10.1097/00008390-199304000-00006. [DOI] [PubMed] [Google Scholar]
  56. Mahvi D. M., Burkholder J. K., Turner J., Culp J., Malter J. S., Sondel P. M., Yang N. S. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum Gene Ther. 1996 Aug 20;7(13):1535–1543. doi: 10.1089/hum.1996.7.13-1535. [DOI] [PubMed] [Google Scholar]
  57. Marcel T., Grausz J. D. The TMC Worldwide Gene Therapy Enrollment Report, end 1996. Hum Gene Ther. 1997 Apr 10;8(6):775–800. doi: 10.1089/hum.1997.8.6-775. [DOI] [PubMed] [Google Scholar]
  58. Massagué J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990;6:597–641. doi: 10.1146/annurev.cb.06.110190.003121. [DOI] [PubMed] [Google Scholar]
  59. Mastrangelo M. J., Schultz S., Kane M., Berd D. Newer immunologic approaches to the treatment of patients with melanoma. Semin Oncol. 1988 Dec;15(6):589–594. [PubMed] [Google Scholar]
  60. Merrouche Y., Negrier S., Bain C., Combaret V., Mercatello A., Coronel B., Moskovtchenko J. F., Tolstoshev P., Moen R., Philip T. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol. 1995 Feb;13(2):410–418. doi: 10.1200/JCO.1995.13.2.410. [DOI] [PubMed] [Google Scholar]
  61. Miller A. R., McBride W. H., Hunt K., Economou J. S. Cytokine-mediated gene therapy for cancer. Ann Surg Oncol. 1994 Sep;1(5):436–450. doi: 10.1007/BF02303818. [DOI] [PubMed] [Google Scholar]
  62. Mitchell M. S., Harel W., Kempf R. A., Hu E., Kan-Mitchell J., Boswell W. D., Dean G., Stevenson L. Active-specific immunotherapy for melanoma. J Clin Oncol. 1990 May;8(5):856–869. doi: 10.1200/JCO.1990.8.5.856. [DOI] [PubMed] [Google Scholar]
  63. Morecki S., Karson E., Cornetta K., Kasid A., Aebersold P., Blaese R. M., Anderson W. F., Rosenberg S. A. Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells. Cancer Immunol Immunother. 1991;32(6):342–352. doi: 10.1007/BF01741329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Morton D. L., Foshag L. J., Hoon D. S., Nizze J. A., Famatiga E., Wanek L. A., Chang C., Davtyan D. G., Gupta R. K., Elashoff R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 1992 Oct;216(4):463–482. doi: 10.1097/00000658-199210000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Nabel G. J., Gordon D., Bishop D. K., Nickoloff B. J., Yang Z. Y., Aruga A., Cameron M. J., Nabel E. G., Chang A. E. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15388–15393. doi: 10.1073/pnas.93.26.15388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Nabel G. J., Nabel E. G., Yang Z. Y., Fox B. A., Plautz G. E., Gao X., Huang L., Shu S., Gordon D., Chang A. E. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307–11311. doi: 10.1073/pnas.90.23.11307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Nagata S. Fas ligand and immune evasion. Nat Med. 1996 Dec;2(12):1306–1307. doi: 10.1038/nm1296-1306. [DOI] [PubMed] [Google Scholar]
  68. Nagata S., Golstein P. The Fas death factor. Science. 1995 Mar 10;267(5203):1449–1456. doi: 10.1126/science.7533326. [DOI] [PubMed] [Google Scholar]
  69. Nowak J., Cohen E. P., Graf L. H., Jr Cytotoxic activity toward mouse melanoma following immunization of mice with transfected cells expressing a human melanoma-associated antigen. Cancer Immunol Immunother. 1991;33(2):91–96. doi: 10.1007/BF01742535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Park J. A., Wang E., Kurt R. A., Schluter S. F., Hersh E. M., Akporiaye E. T. Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther. 1997 Jan-Feb;4(1):42–50. [PubMed] [Google Scholar]
  71. Parker S. E., Khatibi S., Margalith M., Anderson D., Yankauckas M., Gromkowski S. H., Latimer T., Lew D., Marquet M., Manthorpe M. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther. 1996 May-Jun;3(3):175–185. [PubMed] [Google Scholar]
  72. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1997. CA Cancer J Clin. 1997 Jan-Feb;47(1):5–27. doi: 10.3322/canjclin.47.1.5. [DOI] [PubMed] [Google Scholar]
  73. Porgador A., Feldman M., Eisenbach L. Immunotherapy of tumor metastasis via gene therapy. Nat Immun. 1994 Mar-Jun;13(2-3):113–130. [PubMed] [Google Scholar]
  74. Qin H., Chatterjee S. K. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum Gene Ther. 1996 Oct 1;7(15):1853–1860. doi: 10.1089/hum.1996.7.15-1853. [DOI] [PubMed] [Google Scholar]
  75. Quintin-Colonna F., Devauchelle P., Fradelizi D., Mourot B., Faure T., Kourilsky P., Roth C., Mehtali M. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther. 1996 Dec;3(12):1104–1112. [PubMed] [Google Scholar]
  76. Real F. X., Mattes M. J., Houghton A. N., Oettgen H. F., Lloyd K. O., Old L. J. Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med. 1984 Oct 1;160(4):1219–1233. doi: 10.1084/jem.160.4.1219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Reisfeld R. A. Report of the International Consensus Conference on Human Melanoma Antigens, Lausanne, Switzerland, 12-14 November, 1992. Melanoma Res. 1993 Jun;3(3):209–217. [PubMed] [Google Scholar]
  78. Rettig W. J., Real F. X., Spengler B. A., Biedler J. L., Old L. J. Human melanoma proteoglycan: expression in hybrids controlled by intrinsic and extrinsic signals. Science. 1986 Mar 14;231(4743):1281–1284. doi: 10.1126/science.3633135. [DOI] [PubMed] [Google Scholar]
  79. Robbins P. F., el-Gamil M., Kawakami Y., Stevens E., Yannelli J. R., Rosenberg S. A. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 1994 Jun 15;54(12):3124–3126. [PubMed] [Google Scholar]
  80. Rosenberg S. A., Aebersold P., Cornetta K., Kasid A., Morgan R. A., Moen R., Karson E. M., Lotze M. T., Yang J. C., Topalian S. L. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990 Aug 30;323(9):570–578. doi: 10.1056/NEJM199008303230904. [DOI] [PubMed] [Google Scholar]
  81. Rosenberg S. A. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst. 1996 Nov 20;88(22):1635–1644. doi: 10.1093/jnci/88.22.1635. [DOI] [PubMed] [Google Scholar]
  82. Rosenberg S. A. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J Sci Am. 1995 Jul-Aug;1(2):90–100. [PubMed] [Google Scholar]
  83. Rubin J., Galanis E., Pitot H. C., Richardson R. L., Burch P. A., Charboneau J. W., Reading C. C., Lewis B. D., Stahl S., Akporiaye E. T. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther. 1997 May;4(5):419–425. doi: 10.1038/sj.gt.3300396. [DOI] [PubMed] [Google Scholar]
  84. Sage E. H. Terms of attachment: SPARC and tumorigenesis. Nat Med. 1997 Feb;3(2):144–146. doi: 10.1038/nm0297-144. [DOI] [PubMed] [Google Scholar]
  85. Sato T., McCue P., Masuoka K., Salwen S., Lattime E. C., Mastrangelo M. J., Berd D. Interleukin 10 production by human melanoma. Clin Cancer Res. 1996 Aug;2(8):1383–1390. [PubMed] [Google Scholar]
  86. Seino K., Kayagaki N., Okumura K., Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med. 1997 Feb;3(2):165–170. doi: 10.1038/nm0297-165. [DOI] [PubMed] [Google Scholar]
  87. Shiku H., Takahashi T., Oettgen H. F. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J Exp Med. 1976 Oct 1;144(4):873–881. doi: 10.1084/jem.144.4.873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Shiku H., Takahashi T., Resnick L. A., Oettgen H. F., Old L. J. Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics. J Exp Med. 1977 Mar 1;145(3):784–789. doi: 10.1084/jem.145.3.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Stopeck A. T., Hersh E. M., Akporiaye E. T., Harris D. T., Grogan T., Unger E., Warneke J., Schluter S. F., Stahl S. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol. 1997 Jan;15(1):341–349. doi: 10.1200/JCO.1997.15.1.341. [DOI] [PubMed] [Google Scholar]
  90. Strand S., Hofmann W. J., Hug H., Müller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med. 1996 Dec;2(12):1361–1366. doi: 10.1038/nm1296-1361. [DOI] [PubMed] [Google Scholar]
  91. Suminami Y., Elder E. M., Lotze M. T., Whiteside T. L. In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother Emphasis Tumor Immunol. 1995 May;17(4):238–248. doi: 10.1097/00002371-199505000-00006. [DOI] [PubMed] [Google Scholar]
  92. Thörn M., Adami H. O., Bergström R., Ringborg U., Krusemo U. B. Trends in survival from malignant melanoma: remarkable improvement in 23 years. J Natl Cancer Inst. 1989 Apr 19;81(8):611–617. doi: 10.1093/jnci/81.8.611. [DOI] [PubMed] [Google Scholar]
  93. Townsend S. E., Allison J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993 Jan 15;259(5093):368–370. doi: 10.1126/science.7678351. [DOI] [PubMed] [Google Scholar]
  94. Uchiyama A., Hoon D. S., Morisaki T., Kaneda Y., Yuzuki D. H., Morton D. L. Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. Cancer Res. 1993 Mar 1;53(5):949–952. [PubMed] [Google Scholar]
  95. Uckert W., Walther W. Retrovirus-mediated gene transfer in cancer therapy. Pharmacol Ther. 1994 Sep;63(3):323–347. doi: 10.1016/0163-7258(94)90029-9. [DOI] [PubMed] [Google Scholar]
  96. Weber J. S., Rosenberg S. A. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 1988 Oct 15;48(20):5818–5824. [PubMed] [Google Scholar]
  97. Yang J. P., Huang L. Direct gene transfer to mouse melanoma by intratumor injection of free DNA. Gene Ther. 1996 Jun;3(6):542–548. [PubMed] [Google Scholar]
  98. Zea A. H., Curti B. D., Longo D. L., Alvord W. G., Strobl S. L., Mizoguchi H., Creekmore S. P., O'Shea J. J., Powers G. C., Urba W. J. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res. 1995 Nov;1(11):1327–1335. [PubMed] [Google Scholar]
  99. Zitvogel L., Couderc B., Mayordomo J. I., Robbins P. D., Lotze M. T., Storkus W. J. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann N Y Acad Sci. 1996 Oct 31;795:284–293. doi: 10.1111/j.1749-6632.1996.tb52678.x. [DOI] [PubMed] [Google Scholar]
  100. van Duinen S. G., Ruiter D. J., Broecker E. B., van der Velde E. A., Sorg C., Welvaart K., Ferrone S. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res. 1988 Feb 15;48(4):1019–1025. [PubMed] [Google Scholar]
  101. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13;254(5038):1643–1647. doi: 10.1126/science.1840703. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ

RESOURCES